LONDON--(BUSINESS WIRE)--RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that it has received CE marking approval for StronBone™ bioactive glass with Strontium, the first product that will be commercialized from RepRegen’s repair-and-regeneration platform of ‘smart’ biomaterials for hard tissue, such as bone.

“This European regulatory approval enables us to fast-forward the discussions we are having with several potential strategic partners about our hard tissue platform, in general, and our StronBone product, in particular,” said Ian Brown, RepRegen’s CEO.

“We have previously said that the business opportunities ahead of RepRegen are significant and that some of these opportunities are near-term,” added Chairman Dr. Stephen Rietiker. “The Company’s ‘smart’ biomaterials related to its hard tissue platform represent great new medical device products for the orthopedic biomaterials market sector that will be well-received.”